Mitsubishi Tanabe Pharma Corporation has announced that a Phase III trial of its Parkinson’s disease candidate has met its primary endpoint.

[Farooqji]

Patients in the experimental group of ND0612 demonstrated favourable efficacy over IR-LD/CD. Data showed a statistically significant increase (p<0.0001) of 1.72 hours in “ON” time without troublesome dyskinesia. The trial also demonstrated positive and clinically meaningful results for the first four secondary endpoints, including a reduction of “OFF” time (p<0.0001).

clinicaltrialsarena.com/new...